Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Cadence to File NDA in 2009 for Injectable Acetaminophen Product
RxTrials Institute Drug Pipeline Alert
Dec. 24, 2008 | Vol. 6 No. 52
Cadence to File NDA in 2009 for Injectable Acetaminophen Product
Cadence Pharmaceuticals reported positive results from a Phase III trial testing its injectable acetaminophen product Acetavance as a treatment for postoperative pain.
The trial tested the product in 244 patients after they had laparoscopic abdominal surgery. The study met its primary endpoint of a statistically significant reduction in summed pain intensity differences from baseline over 24 hours.
The adult clinical development program for Acetavance is complete, the company says in a statement. The company plans to file an NDA for the drug to treat acute pain and fever in the second half of next year.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.